氯卡色林
![]() | |
![]() | |
| 臨床資料 | |
|---|---|
| 商品名 | Belviq |
| 其他名稱 | APD-356 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a613014 |
| 核准狀況 | |
| 给药途径 | 口服 |
| 藥物類別 | 5-羟色胺2C受体激动剂 |
| ATC碼 | |
| 法律規範狀態 | |
| 法律規範 | |
| 藥物動力學數據 | |
| 血漿蛋白結合率 | 70%[2] |
| 药物代谢 | 大部分经肝脏[2] |
| 生物半衰期 | 11小时[2] |
| 排泄途徑 | 肾脏(92.3%)、粪便(2.2%)[2] |
| 识别信息 | |
| |
| CAS号 | 616202-92-7 |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.237.138 |
| 化学信息 | |
| 化学式 | C11H14ClN |
| 摩尔质量 | 195.69 g·mol−1 |
| 3D模型(JSmol) | |
| |
| |
氯卡色林(英語:Lorcaserin,商品名Belviq),又名洛卡色林、绿卡色林,是由阿里那制药公司(Arena Pharmaceuticals)研发的一种减肥药。[4][5]它通过激活下丘脑中控制食欲的5-羟色胺2C受体来抑制食欲。[6]
氯卡色林于2012年获批上市,在2020年因被发现增加使用者的患癌风险而在美国撤市。[1][7]
参考资料
- ^ 1.0 1.1 FDA requests the withdrawal of the weight-loss drug Belviq, Belviq XR (lorcaserin) from the market. U.S. Food and Drug Administration (FDA). 14 January 2020 [1 April 2020]. (原始内容存档于13 April 2020).
- ^ 2.0 2.1 2.2 2.3 Belviq (lorcaserin hydrochloride) tablet [Eisai, Inc]. DailyMed. Eisai, Inc. August 2012 [21 October 2013]. (原始内容存档于21 October 2013).
- ^ Lorcaserin Use During Pregnancy. Drugs.com. 4 November 2019 [14 January 2020]. (原始内容存档于2020-01-15).
- ^ FDA approves Belviq to treat some overweight or obese adults. U.S. Food and Drug Administration (FDA) (新闻稿). 27 June 2012 [14 January 2020]. (原始内容存档于1 October 2012).
本文含有此來源中屬於公有领域的内容。
- ^ Belviq. Trademarkia. 23 Jun 2011 [27 June 2012]. (原始内容存档于30 June 2012).
- ^ Shukla AP, Kumar RB, Aronne LJ. Lorcaserin Hcl for the treatment of obesity. Expert Opinion on Pharmacotherapy. 2015, 16 (16): 2531–8. PMID 26472579. S2CID 44520532. doi:10.1517/14656566.2015.1096345.
- ^ Belviq, Belviq XR (lorcaserin) by Eisai: Drug Safety Communication - FDA Requests Withdrawal of Weight-Loss Drug. U.S. Food and Drug Administration (FDA). 13 February 2020 [18 February 2020]. (原始内容存档于2020-02-24).
外部链接
- Lorcaserin. Drug Information Portal. U.S. National Library of Medicine. (原始内容存档于24 January 2018).

